Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis

Asia-Pacific Journal of Clinical Oncology

Volumn 14, Issue 3, 2018, Pages 141-152

  Man, Johnathan ^a   Ritchie, Georgia ^a,b   Links, Matthew ^a   Lord, Sally ^c,d   Lee, Chee Khoon ^a,c  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF NOTRE DAME   (Australia)

Author keywords

cancer; chemotherapy; immunotherapy; PD 1 blockade; toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ASSOCIATED ANTIGEN 4 INHIBITOR; PROGRAMMED DEATH 1 INHIBITOR; PROGRAMMED DEATH LIGAND 1 INHIBITOR; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; ADVERSE OUTCOME; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENDOCRINE DISEASE; FEBRILE NEUTROPENIA; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; META ANALYSIS; MONOTHERAPY; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT RISK; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; ANTAGONISTS AND INHIBITORS; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85040722552     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12838     Document Type: Article

References (37)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
2. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. New Engl J Med. 2015;372(4):320–330.
3. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384.
4. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–918.
5. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med. 2011;364(26):2517–2526.
6. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma.[Erratum appears in N Engl J Med. 2010 Sep 23;363(13):1290]. N Engl J Med. 2010;363(8):711–723.
7. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894.
8. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
9. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017.
10. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
11. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
12. Herbst RS, Baas P, Kim D, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet Oncol. 2015.
13. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–1846.
14. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
15. Niraula S, Seruga B, Ocana A, et al. The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol. 2012;30(24):3012–3019.
16. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
17. Higgins J, Deeks J, Altman D. Metaanalysis of rare events. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions (version 510): The Cochrane Collaboration; 2011.
18. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23(9):1351–1375.
19. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616–622.
20. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study.[Erratum appears in J Clin Oncol. 2012 Oct 10;30(29):3654]. J Clin Oncol. 2012;30(17):2046–2054.
21. Barlesi F, Park K, Ciardiello F, et al. Primary analysis from OAK, a randomised phase III study comparing atezolizumab with docetaxel in advanced NSCLC. Ann Oncol. 2016;27(Suppl 6):vi552–vi87.
22. Socinski M, Creelan B, Horn L, et al. CheckMate 026: A phase III trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand (PD-L1) - positive NSCLC. Ann Oncol. 2016;27(Suppl 6):vi552–vi87.
23. Langer CL, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508.
24. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75–83.
25. Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740–3750.
26. Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40–47.
27. Ferris RL, Blumenschein GR, Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867.
28. Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785–792.
29. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709–717.
30. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi F. Incidence of programmed cell death 1 inhibitor–related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607–1616.
31. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): Results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41.
32. Di Maio M, Gallo C, Leighl NB, et al. Symptomatic Toxicities experienced during anticancer treatment: Agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015;33(8):910–916.
33. Yazici Y. Some concerns about adverse event reporting in randomized clinical trials. Bull NYU Hosp Jt Dis. 2008;66(2):143–145.
34. Singh S, Loke YK. Drug safety assessment in clinical trials: Methodological challenges and opportunities. Trials. 2012;13:138.
35. Penninckx B, Van de Voorde WM, Casado A, Reed N, Moulin C, Karrasch M. A systemic review of Toxic Death in clinical oncology trials: An Achilles/' heel in safety reporting revisited. Br J Cancer. 2012;107(1):1–6.
36. Edwards A, Elwyn G. Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision. Health Expect. 2006;9(4):307–320.
37. Thanarajasingam G, Atherton PJ, Novotny PJ, Loprinzi CL, Sloan JA, Grothey A. Longitudinal adverse event assessment in oncology clinical trials: The Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Lancet Oncol. 2016;17(5):663–670.